Evidence map›Paper›PMID 42205730›Full record

ArticleClinical and translational radiation oncology2026

Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer.

Anna M Dornisch, Mariluz Rojo Domingo, Roberta Vezza Alexander, Christopher C Conlin, Son Do, Rana R McKay, Vitali Moiseenko, Michael A Liss, Jasmine Liu, Todd Pawlicki and 10 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06990542 (RAdiation Dose TAiloRing Guided by Enhanced Targeting), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06990542 phase2recruitingnot on this map

RAdiation Dose TAiloRing Guided by Enhanced Targeting

TypeinterventionalSponsorUniversity of California, San DiegoRan2025 to 2033Enrolled150ConditionsProstate CancerArmsImage-guided tumor-focused radiation therapy
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Anna M DornischDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.
Mariluz Rojo DomingoDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.
Roberta Vezza AlexanderMoores Cancer Center, University of California San Diego, La Jolla, USA.
Christopher C ConlinDepartment of Radiology, University of California San Diego, La Jolla, USA.
Son DoDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.
Rana R McKayDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.
Vitali MoiseenkoDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.
Michael A LissDepartment of Urology, University of California San Diego, La Jolla, USA.
Jasmine LiuDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.
Todd PawlickiDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.
Samuel PenaMoores Cancer Center, University of California San Diego, La Jolla, USA.
Edmund M QiaoDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.
Brent S RoseDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.
Rhea RupareliyaDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.
Ajay P SandhuDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.
Jessica ScholeyDepartment of Radiation Oncology, University of California San Francisco, San Francisco, USA.
Steven N SeyedinDepartment of Radiation Oncology, University of California San Francisco, San Francisco, USA.
James J UrbanicDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.
Lee-Jen WeiDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, USA.
Tyler M SeibertDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Definitive radiotherapy (RT) for prostate cancer (PC) with dose intensification and/or focal boosting has excellent oncologic outcomes, but many patients experience adverse events. Dose escalation to the whole prostate improves outcomes at the expense of increased late adverse events. Intraprostatic recurrence after definitive RT typically occurs at the site of the primary tumor, suggesting that dose to the site of the dominant lesion is an important predictor of future failure. The efficacy and safety of tumor-focused RT compared to that of standard RT for definitive treatment of localized PC has not been assessed. RadTARGET (RAdiation Dose TAiloRing Guided by Enhanced Targeting; NCT06990542) is a phase II randomized trial that aims to demonstrate superior safety of image-guided, tumor-focused RT compared to standard RT for acute genitourinary (GU) or gastrointestinal (GI) in the setting of definitive RT for intermediate- and high-risk PC. The study intervention is image-guided, tumor-focused RT with dose intensification of cancer visible on imaging and dose de-intensification to remaining prostate. Patients will be randomized to two arms: those who receive standard RT dose and those that receive tumor-focused RT. The study population will be patients with intermediate- or high-risk PC planning to undergo definitive RT with or without systemic therapy. The primary endpoint to compare between randomized arms is acute GU or GI grade ≥2 adverse events. Participant and study duration are 5 years and 8 years, respectively. RadTARGET will compare the efficacy and safety of tumor-focused RT to that of standard RT for definitive treatment of localized PC. We hypothesize that the tumor-focused approach will substantially reduce adverse events after prostate RT while retaining high efficacy. If this hypothesis is confirmed, we will conclude that a phase III randomized control trial is warranted to formally establish oncologic non-inferiority compared to the current standard of whole-gland dose escalation.

Indexed as

Diffusion MRIDose de-escalationFocal therapyGastrointestinal toxicityGenitourinary toxicityPelvic radiation therapyPSMA PETQuality of lifeRestriction spectrum imagingTumor boost

Identifiers

PMID42205730
PMCPMC13202547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.